logo
How to Find Safe Eye Drops Now That 75,000 Cases Were Just Recalled

How to Find Safe Eye Drops Now That 75,000 Cases Were Just Recalled

CNET16-05-2025

According to the Food and Drug Administration, over 75,000 cases of AvKare eye drops and artificial tears were recalled due to deviations from Current Good Manufacturing Practices (cGMP). CGMP regulations ensure the "identity, strength, quality and purity of drug products." Shipped from May 26, 2023, through April 21, 2025, AvKare states that these are the items that were recalled:
NDC# 50268-043-15 Artificial Tears Ophthalmic Solution
NDC# 50268-066-15 Carboxymethylcellulose Sodium Ophthalmic Gel 1%
NDC# 50268-068-15 Carboxymethylcellulose Sodium Ophthalmic Solution
NDC# 50268-126-15 Lubricant Eye Drops Solution
NDC# 50268-678-15 Polyvinyl Alcohol Ophthalmic Solution
If you purchased any of these eye drops, stop using them. To get a refund for your purchase, AvKare states that you must complete the "Quantity to Return" column and customer information block on its recall form. You can then fax this to 931-292-6229 or email customerservice@avkare.com.
How to find safe eye drops
Eye drops are used to treat many conditions, from minor irritants to chronic vision problems. Optometrists and ophthalmologists can prescribe them to help patients heal after surgeries and to prevent infections. You can buy many of them over the counter to deal with dry eyes or an allergy flare-up.
With so many options available, careful research is critical to ensure you choose the best eye drops for your particular eye issues. Ingredients vary widely by the type of eye drops, and using the wrong type can cause more problems than it solves.
Know the different types of eye drops
Some eye drops can be purchased over the counter, while others require a prescription. The most common ones include:
Lubricating drops : Also known as artificial tears, these are designed to relieve dryness and any associated redness or irritation. Common active ingredients include polyethylene glycol and propylene glycol. The nighttime version of these drops is thicker and comes in a gel or ointment.
: Also known as artificial tears, these are designed to relieve dryness and any associated redness or irritation. Common active ingredients include polyethylene glycol and propylene glycol. The nighttime version of these drops is thicker and comes in a gel or ointment. Anti-allergy drops : Antihistamine drops relieve itchiness, redness and other irritation caused by reactions to allergens like pollen or pet dander. Several options are on the market, and active ingredients vary by brand. Common ingredients include ketotifen, olopatadine, carboxymethylcellulose and glycerin.
: Antihistamine drops relieve itchiness, redness and other irritation caused by reactions to allergens like pollen or pet dander. Several options are on the market, and active ingredients vary by brand. Common ingredients include ketotifen, olopatadine, carboxymethylcellulose and glycerin. Anti-redness drops: These eye drops usually contain tetrahydrozoline or brimonidine to reduce the swelling of the blood vessels in your eye. They're designed to be used sparingly.
These eye drops usually contain tetrahydrozoline or brimonidine to reduce the swelling of the blood vessels in your eye. They're designed to be used sparingly. Antibiotic drops : These prescription eye drops treat infections such as pink eye or corneal ulcers caused by Pseudomonas aeruginosa. Common drugs include gentamicin sulfate and ciprofloxacin.
: These prescription eye drops treat infections such as pink eye or corneal ulcers caused by Pseudomonas aeruginosa. Common drugs include gentamicin sulfate and ciprofloxacin. Steroid drops: Steroid eye drops are prescribed to reduce symptoms of inflammation like swelling or redness -- for example, after eye surgery.
Steroid eye drops are prescribed to reduce symptoms of inflammation like swelling or redness -- for example, after eye surgery. Drops for treating certain health conditions: Eye doctors may prescribe various other types of eye drops to treat a range of conditions, like myopia and glaucoma.
Consult your eye doctor
One way to avoid problems with recalled over-the-counter brands is to go to a professional, rather than picking out eye drops yourself. In fact, you should always check with your eye doctor about the right type to buy and how to use them safely.
"People don't always pay attention to what they're buying or why they're buying it," said Dr. Ronald Benner, an optometrist at Southern Montana Optometric Center who has been practicing for more than 30 years. "We strongly recommend that all patients consult with their local optometrist to make sure that they're using the right drop for the right reasons."Double-check the brand before you apply the drops
With so many products being recalled (even some from major brands), the easiest way to stay up-to-date on whether your particular eye product is safe is to Google the specific product name and see if it's been listed in any FDA or CDC warnings, or has been recalled. Take a minute to do this before you put it in your eyes in case anything has changed since you initially bought it.
"Ophthalmic drug products potentially pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body's natural defenses," the FDA wrote in a Oct. 27 press release. This makes it especially important to avoid products that might not be completely sterile or use safe ingredients.
Identify the cause of your eye concerns
Because there are so many different eye issues, finding the underlying problem is essential for choosing the right treatment. Benner notes that many patients choose drops that only provide temporary relief without addressing the underlying cause. This can lead to endless reliance on drops or even make problems worse.
Dry eyes, for instance, have many potential causes. They may be a result of allergies, or your time in front of a computer might be a factor. Or you might not naturally produce enough tears. Treatment for each of these causes would be quite different.
"Get the actual help to solve the problem and don't just treat a symptom," said Benner.
Read more: 12 Best Foods for Eye Health
Consider preservative vs. preservative-free options
Most medications, including eye drops, include preservatives to help keep bugs and bacteria out. As Benner notes, they're meant to protect consumers, but they may not always be the best choice. In some cases, preservatives can irritate the tissues of the eyes.
"The preservative can cause the problems that the drop is supposed to help alleviate," he said. "For many people, using a preservative-free version is much healthier and much more comfortable for the eye."
In his practice, Benner always guides patients who are complaining of sensitivity or had recent surgeries to use eye drops that don't contain preservatives. Often, people who use eye drops regularly will benefit from avoiding preservatives. Again, Benner stresses that your eye doctor can steer you in the right direction based on your situation.
Consider allergen-free eye drops for sensitive eyes
Preservatives aren't the only potential irritant in eye drops. Antibiotics, beta-blocking agents, corticosteroids, antioxidants and other ingredients have all been associated with eye irritation in some patients. Before you use any eye drops, it's a good idea to consult your eye doctor and read ingredient labels to note any potential allergens.
Med-Ved/Getty Images
Safety precautions for using eye drops
Choosing the right eye drops is only the first step in the process. Once you have the correct product in hand, be sure you know how to put in eye drops so you don't cause any harm to your eyes.
Follow the instructions on the label
Each bottle contains instructions for proper application. These ensure you use the proper dose and that it spreads over the whole surface of your eye. Instructions also include guidance on how often to apply the drops and reactions that indicate you should stop. Never use eye drops without reading these instructions.
Wash your hands before each use
Your hands may contain dirt, bacteria or other irritants that could affect your eyes, and there's no way to avoid putting your fingers on your eyelids when applying drops. At best, this might offset the benefits of using eye drops. At worst, it might create new problems. Always wash your hands thoroughly with soap and water before applying eye drops.
Avoid contamination
It's also important to keep the eye drop bottle itself sterile and free from germs, as this could result in cross-contamination between your eyes or with another user. Aside from washing your hands before you apply the drops, avoid touching the dropper to your eyes or touching the tip with your hands. Always put the cap on immediately after use and store the eye drops in a clean, sterile environment.
Be on the lookout for expiration dates
All eye drops have an expiration date, which is printed on the bottle. They're usually good for one to two years unopened, but this period may be shorter for eye drops that don't have preservatives.
Keep in mind that preservatives and other active ingredients begin to break down once you open the bottle. This makes them less effective and increases your chances of infection. Most manufacturers recommend throwing away eye drops after they've been open for 28 days. Single-application vials should be discarded immediately after use.
ProfessionalStudioImages/Getty Images
Tips for correct application
Even with the correct, clean drops in hand, it's important to know how to put eye drops in properly to maximize their effectiveness and reduce your chances of having a reaction. Here are a few steps you can take to correctly apply most eye drops:
Wash your hands. Remove the cap and place it in a clean, dry location. Tilt your head back while pulling down your lower eyelid. Squeeze the proper amount of drops into the sac created by pulling down your lower lid. Release your eyelid and close your eyes for 30 seconds to allow the solution to spread across your eye. Repeat on your other eye if needed.
When in doubt, be sure to review the instructions on the bottle.
Watch for potential side effects
Depending on the type of product and any allergies you may have, eye drops can cause a range of side effects. Some of the most common include redness, swelling, itching or soreness. More serious side effects may include prolonged burning, discharge, or even hives, swelling, wheezing, dizziness or vomiting.
These side effects could be the result of an allergic reaction, or they may be a sign of infection or a foreign body irritating your eye. As Benner notes, the only way to be sure is to contact your eye doctor.
"If the eye stays red or gets redder, those people should be seen ASAP," he said. "If there's mucus, if there's sharp pain in the eye, if there's discharge out of the eye, patients should be seen right away."
TimHow to store and travel with eye drops
Like any other medication, eye drops must be stored properly to prevent spoilage or the development of bacteria. Be sure to follow the manufacturer's instructions for storage location and temperature to ensure your drops stay effective and safe to use.
Proper storage can be especially difficult to achieve when traveling. If you know your suitcase will sit in a hot car or airplane luggage compartment, for instance, you may want to keep your eye drops with you or run them to your hotel room sooner rather than later. Always check to ensure the lid is secure and free from any risk of contamination.
Too long; didn't read
Like sunglasses and other eye care products, eye drops are an important tool for maintaining eye health. Whether you get them by prescription or over the counter, it's essential to consult with your eye doctor about the correct product and learn how to put eye drops in safely. Eye drops are generally safe to use, but you should always report side effects to your doctor right away -- and avoid using any products that have been recalled.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Firing Of Vaccine And Cancer Advice Panels Raises Question, What Next?
Firing Of Vaccine And Cancer Advice Panels Raises Question, What Next?

Forbes

time15 minutes ago

  • Forbes

Firing Of Vaccine And Cancer Advice Panels Raises Question, What Next?

WASHINGTON, DC: Secretary of Health and Human Services Robert F. Kennedy Jr. testifies before the ... More Senate Committee on Health, Education, Labor, and Pensions on Capitol Hill on May 20, 2025. Kennedy testified Department of HHS's proposed 2026 fiscal year budget.(Photo by) Earlier this year, the National Institutes of Health dismantled the National Cancer Institute's Board of Scientific Advisors, which had 28 members. And now Health and Human Services Secretary Robert F. Kennedy Jr fired the entire 17-member Advisory Committee on Immunization Practices that provides recommendations on vaccines to the Centers for Disease Control and Prevention. This raises the question, who's going to do the advising? With no replacement forthcoming, at NCI it would appear that the National Cancer Advisory Board will have to go it alone. At ACIP, it's likely Kennedy will appoint people to the advisory committee without a vaccine industry pedigree, including like-minded vaccine skeptics. The importance of having independent expert panels in the oncology and vaccine spaces is hard to overstate. Cancer is America's second-leading cause of death. NCI is the nation's premier funder of cancer research. And regarding vaccines, from smallpox inoculations—which began in the late 18th century and ended when the disease was eradicated in the 1970s—to mumps, rubella, tetanus, diphtheria, polio, measles, hepatitis B, human papilloma virus, respiratory syncytial virus, pneumococcal and COVID-19 immunizations, vaccinations have saved millions of lives and prevented life-threatening illnesses from occurring. What happens next in terms of decisions by Kennedy and the various HHS agencies will matter considerably to public health. Kennedy seeks to radically reshape the vaccine policy landscape as he ousts CDC's ACIP, which advises the CDC director on which vaccines approved by the Food and Drug Administration should be used; for example, recommending which groups of people ought to be vaccinated, at what doses and when. For decades, ACIP's guidance has been based on an independent, non-politicized review of the peer-reviewed scientific research as well as debate among the committee experts. ACIP's guidance is not binding, though CDC almost always follows it and provides recommendations to the public on what is to be included in the United States adult and childhood immunization schedules. In a press release issued by the Department of HHS on June 9th, Kennedy says he's doing this in order to restore the public's trust in vaccine science in America. It's unknown who Kennedy will hire to replace committee members, but it's possible that at least some of the people he appoints will share his skeptical views of vaccines. The Department of HHS said ACIP will still meet June 25-27, but with new membership. This means that between now and then, presumably we'll know the list of new members. In determining who's to be on the ACIP committee, Kennedy says he wants to eliminate conflicts of interest that panel members may have with the industry. But Science describes an already existing process in place for vetting candidates and probing for potential conflicts of interest. Indeed, looking at the current ACIP members, conflicts of interest aren't readily apparent among the large number of academics, a chief medical officer of a community health center, a state public health official and the owner of a family medicine practice. But Kennedy seems to view them differently. Given that several members have prior to their ACIP membership pursued research funded in part by grants to universities from the pharmaceutical industry, while others have advocated for certain childhood vaccinations, in Kennedy's eyes they're probably seen as part of the vaccine establishment. The NIH dismissed all 28 members of the Board of Scientific Advisors to the National Cancer Institute in late April. This board had been reviewing NCI-funded extramural research and education projects for nearly three decades, often doing its work in conjunction with the National Cancer Advisory Board. In making the termination decision, the NIH director Jay Bhattacharya cited a presidential executive order calling for the culling of 'unnecessary' federal committees. This order also included an edict that the HHS Secretary end the Advisory Committee on Long COVID and that the Administrator of the Centers for Medicare and Medicaid Services discontinue the Health Equity Advisory Committee The NCI's Board of Scientific Advisors was made up of leading cancer scientists, mostly from academia, across a wide range of disease specialties. Board members did their work as a panel voluntarily, offering a deep level of expertise to the NCI, specifically around setting research priorities and giving the broader scientific community input into the NCI's extramural programs. Whether the still-existing National Cancer Advisory Board can pick up the slack and be as independent are unclear. The NIH didn't just get rid of the NCI's Board of Advisors. The NCI has also begun to face large numbers of staff terminations and closures of programs. As STAT News reported, NIH fired virtually the entire NCI communications team and a substantial number of employees in the Office of Advocacy Relations. The NCI Outstanding Investigator award program was also canceled. More cuts are expected, as the NCI has been ordered to 'significantly' reduce its contracts budget. This budget can cover, among other things, support for clinical trials, certain lab scientists, a cancer registry to collect, store and manage data on persons with cancer, scientific databases and a repair service for critical lab equipment. On top of this, the New York Times is tallying the full extent of the cuts in research grant funding across all parts of the NIH, including the NCI. Currently, at least 2,500 grants have been canceled or delayed, impacting many therapeutic areas such as cancer, but also vaccine development and research on how to improve vaccination outreach.

PlushCare Launches Enhanced Online Weight Loss Program to Expand National Access to GLP-1 Prescriptions Through Board-Certified Doctors
PlushCare Launches Enhanced Online Weight Loss Program to Expand National Access to GLP-1 Prescriptions Through Board-Certified Doctors

Yahoo

time17 minutes ago

  • Yahoo

PlushCare Launches Enhanced Online Weight Loss Program to Expand National Access to GLP-1 Prescriptions Through Board-Certified Doctors

Secure Online Access to GLP-1 Weight Loss Medications Like Semaglutide Now Available Nationwide Through PlushCare's Updated Virtual Health Platform San Francisco, June 10, 2025 (GLOBE NEWSWIRE) -- PlushCare, a leading virtual healthcare platform, has announced a significant upgrade to its online Weight Loss Program, enabling greater access to GLP-1-based prescription treatments such as semaglutide through board-certified physicians. This development marks a critical milestone in the company's mission to provide affordable, clinically supervised weight management across the United States. Accessible at the updated platform streamlines the process for eligible adults to consult with licensed physicians, receive lab work if necessary, and access customized treatment plans—all from the comfort of their homes. 'We're committed to making evidence-based weight loss solutions more accessible through modern telehealth,' said a PlushCare spokesperson. 'Our program is designed to connect people with experienced doctors who can evaluate eligibility for medications like GLP-1s and deliver a personalized plan that fits their health goals.' Expanded Features for 2025 The revamped Weight Loss Program now includes: Nationwide Access to medical providers via secure telehealth appointments Eligibility Evaluation for FDA-approved medications, including semaglutide Personalized Plans tailored to each user's metabolic profile Optional Lab Testing with integrated results for precision treatment Transparent Pricing with no insurance required The platform is optimized for mobile and desktop users, offering a seamless experience from appointment scheduling to prescription delivery. Addressing a Growing National Health Concern According to the CDC, over 40% of U.S. adults struggle with obesity, with rising demand for effective clinical support. PlushCare's integrated virtual care model delivers a scalable solution that removes traditional geographic and scheduling barriers. Patients can typically get started in under 15 minutes by completing an intake form and booking a same-day appointment with a licensed doctor. If clinically appropriate, a prescription is sent to their preferred pharmacy. About PlushCare PlushCare is a virtual primary care and mental health platform that connects patients with top U.S. medical professionals through its secure telehealth platform. With a commitment to quality care, convenience, and evidence-based treatment, PlushCare is redefining access to modern healthcare. For more information, visit Media Contact:PlushCare Media RelationsEmail: press@ 345 California Street, Suite 600, San Francisco, CA 94105, United States SOURCE: PlushCare Disclaimer: This release contains forward-looking statements and should not be considered medical advice. All treatments are subject to clinical evaluation and provider discretion. CONTACT: Email: press@ in to access your portfolio

Vijay Pande, founding partner of a16z bio and health strategy, steps down
Vijay Pande, founding partner of a16z bio and health strategy, steps down

TechCrunch

time27 minutes ago

  • TechCrunch

Vijay Pande, founding partner of a16z bio and health strategy, steps down

In Brief Vijay Pande, a general partner at Andreessen Horowitz who founded the firm's a16z Bio+ Health strategy, announced that he is stepping down from his role. Since its founding in 2014, a16z Bio+ Health has raised four funds of nearly $3 billion each, including a $1.5 billion fund that closed in 2022. However, it's now seeking a much smaller $750 million fifth fund, The Wall Street Journal reported. In January, a16z Bio+ Health announced that it will manage a $500 million biotech fund funded by pharmaceutical giant Eli Lilly. a16z Bio + Health backs digital health startups and companies at the intersection of AI, computation, and biology. Pande's investments include Devoted Health, an individualized medical plan provider; Function Health, a personalized lab testing startup; and Freenome, a company aiming to detect cancer through blood draws. Before joining Andreessen Horowitz, Pande was a professor of chemistry, structural biology, and computer science at Stanford University. The remaining partners on the a16z Bio + Health team are Jorge Conde, Julie Yoo, and Vineeta Agarwala.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store